Analyst Estimates: Here's What Brokers Think Of DiaSorin S.p.A. (BIT:DIA) After Its Interim Report
It's been a good week for DiaSorin S.p.A. (BIT:DIA) shareholders, because the company has just released its latest half-yearly results, and the shares gained 5.5% to €74.50. It was an okay report, and revenues came in at €602m, approximately in line with analyst estimates leading up to the results announcement. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
Taking into account the latest results, the consensus forecast from DiaSorin's 14 analysts is for revenues of €1.23b in 2026. This reflects a reasonable 4.8% improvement in revenue compared to the last 12 months. Before this earnings report, the analysts had been forecasting revenues of €1.23b and earnings per share (EPS) of €3.47 in 2026. Overall, while the analysts have reconfirmed their revenue estimates, the consensus now no longer provides an EPS estimate. This implies that the market believes revenue is more important after these latest results.
View our latest analysis for DiaSorin
We'd also point out that thatthe analysts have made no major changes to their price target of €72.45. The consensus price target is just an average of individual analyst targets, so - it could be handy to see how wide the range of underlying estimates is. The most optimistic DiaSorin analyst has a price target of €90.00 per share, while the most pessimistic values it at €58.00. This shows there is still a bit of diversity in estimates, but analysts don't appear to be totally split on the stock as though it might be a success or failure situation.
Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. One thing stands out from these estimates, which is that DiaSorin is forecast to grow faster in the future than it has in the past, with revenues expected to display 9.8% annualised growth until the end of 2026. If achieved, this would be a much better result than the 1.1% annual decline over the past five years. By contrast, our data suggests that other companies (with analyst coverage) in the industry are forecast to see their revenue grow 5.8% per year. So it looks like DiaSorin is expected to grow faster than its competitors, at least for a while.
The Bottom Line
The clear take away from these updates is that the analysts made no change to their revenue estimates for next year, with the business apparently performing in line with their models. Happily, there were no major changes to revenue forecasts, with the business still expected to grow faster than the wider industry. The consensus price target held steady at €72.45, with the latest estimates not enough to have an impact on their price targets.
We have estimates for DiaSorin from its 14 analysts out to 2028, and you can see them free on our platform here.
Don't forget that there may still be risks. For instance, we've identified 1 warning sign for DiaSorin that you should be aware of.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.